Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Army Medical Department Board Tests Nerve Agent Antidote Auto-Injectors

by Global Biodefense Staff
February 11, 2020

While training during a simulated Chemical, Biological, Radiological, and Nuclear, or CBRN, attack at Joint Base San Antonio-Camp Bullis, a Soldier checks a causality's Mission Oriented Protective Posture, or MOPP, mask. Credit: Jose E. Rodriguez

Nerve agents are the most toxic of the known chemical agents. They are hazards in both liquid and vapor states and can cause death within minutes after exposure. Nerve agents are the primary chemical warfare agent threat because of their high toxicity and effectiveness through multiple routes of entry. They are absorbed through the eyes, respiratory tract and skin.

Ensuring nerve agent antidote auto-injectors are functional and usable are critical in savings lives. These nerve agent antidote auto-injectors are designed to be used in a Chemical, Biological, Radiological and Nuclear, or CBRN, environment.

Recently the U.S. Army Medical Department Board, or USAMEDDBD, assigned to the U.S. Army Medical Center of Excellence at Joint Base San Antonio-Fort Sam Houston, conducted a test of these devices at JBSA-Camp Bullis.

The United States military adopted the auto-injector as the drug delivery device for chemical weapons exposure because of ease of use, packaging durability, and drug product stability under varying storage conditions.

A Soldier wearing Mission Oriented Protective Posture, or MOPP, protective gear simulates using a CBD auto-injector device on a casualty during a field test at Joint Base San Antonio-Camp Bullis. Credit: Jose E. Rodriguez

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, or JPM CBRN Medical, at Fort Detrick, Maryland, requested the AMEDD Board conduct a customer test of the nerve agent antidote auto-injector within the operational environment. The data and test findings collected by the AMEDD Board will be will be provided to JPM CBRN Medical.

The nerve agent antidote auto-injector is a replacement for the currently fielded auto-injector for treatment against nerve agent and insecticide poisoning, adjunctive treatment, and management of agent-induced seizures.

Courtesy photo

The United States military adopted the auto-injector as the drug delivery device because of ease of use, packaging durability, and drug product stability under varying storage conditions.

Soldiers donned Mission Oriented Protective Posture, more commonly known as MOPP protective gear, and tested the auto-injectors in a simulated battlefield exercise complete with smoke grenades. MOPP masks can limit visibility, so the injectors have clear, easy to understand pictorial instructions.

“A lot of these auto-injectors used to have wording, just written instructions,” said Gary Cabigon, an operational tester with the AMEDD Board. “What we learned over the years is that pictures are easier to comprehend, especially in a stressful environment.”

Cabigon said that when under a CBRN attack vital seconds saved in dispensing the auto-injector matter.

Sgt. First Class Elijah Williamson, an AMEDD Board test officer, talked about conducting the test in the field.

U.S. Army Medical Department Board test evaluator Eddie Fields writes down his observations during a similar auto-injector test performed in 2019 at Joint Base San Antonio-Camp Bullis. Credit: Jose E. Rodriguez

“I think it’s great having the training asset at JBSA-Fort Sam Houston,” Williamson said. We have the austere environment where we can create the simulation of the battlefield. We do so much on slides and videos that you want to get hands-on and create that realism out at JBSA-Camp Bullis. You can’t get that in the classroom.”

The nerve agent antidote auto-injectors are designed to deliver an intramuscular injection with a 22-gauge needle with a pressure-activated coil spring mechanism that triggers the needle after removal of the safety cap. When activated, the needle protrudes through the needle end.

Story courtesy U.S. Army, edited for context and format by Global Biodefense.

Tags: Chemical WeaponsEditor PickJPEO-CBRNDMagazine Edition 20 Feb 2020

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy